Trial Profile

Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy - a Phase II Study.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 20 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin liposomal (Primary) ; Lapatinib (Primary)
Indications Advanced breast cancer
Focus Therapeutic Use

Most Recent Events

16 Mar 2012 Planned End Date changed from 1 Dec 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
24 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
10 Mar 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com